This narrative, non-systematic mini-review aims to provide an updated synthesis of the available clinical evidence regarding the potential role of SSRIs in promoting post-stroke recovery beyond their established effects on mood.

A literature search was performed using the PubMed/MEDLINE database up to February 2026. PubMed/MEDLINE was selected as the primary database due to its comprehensive coverage of biomedical literature. The search strategy included combinations of the following keywords: “selective serotonin reuptake inhibitor”, “SSRI”, “fluoxetine”, “sertraline”, “citalopram”, “escitalopram”, “fluvoxamine” AND “stroke”, “cerebrovascular diseases”, “cerebral ischemia”, “neuroplasticity”, “motor recovery”, “cognitive recovery”, AND “rehabilitation”.

Relevant studies were selected based on their clinical relevance to the topic. Priority was given to randomized controlled trials (RCTs), particularly large multicenter studies, as well as stroke-specific clinical investigations. Smaller mechanistic and exploratory studies were included to support the biological rationale and to contextualize domain-specific findings. Only articles published in English were considered. Additional references were identified through manual screening of the reference lists of selected articles.

Given the narrative nature of this review, no formal systematic review protocol or meta-analysis was applied. The evidence is therefore presented in a structured and interpretive manner, taking into account differences in study design, patient populations, treatment timing, and outcome measures. While no formal study quality scoring or risk-of-bias assessment was performed, greater weight was given to higher-quality evidence to support a balanced and transparent interpretation of the available data. Due to the narrative nature of this review, study selection was not performed by duplicate independent reviewers, and no quantitative synthesis was planned.

Based on the available literature identified through the above-described approach, the translation of the biological rationale supporting SSRI use in post-stroke recovery into consistent clinical benefit remains complex.

Over the past two decades, several SSRIs—including fluoxetine (FLX), citalopram (CTP), escitalopram (ESC), and, to a lesser extent, sertraline (SRT) and fluvoxamine (FLV)—have been investigated for their potential to enhance neurological recovery beyond mood stabilization. Early mechanistic and small-scale clinical studies generated enthusiasm by demonstrating improvements in motor performance, cognitive domains, and neurophysiological markers of plasticity. However, the positive findings reported by early studies should be interpreted cautiously because of their relatively small sample sizes, selected populations, and potential susceptibility to type I error and publication bias. In contrast, subsequent large multicenter RCTs yielded neutral results on global functional outcomes and highlighted relevant safety concerns.

This divergence between biological plausibility, domain-specific improvements, and large-scale pragmatic trial outcomes has reshaped the current clinical perspective. The field has progressively shifted from asking whether SSRIs broadly improve post-stroke recovery to identifying which specific agents, patient subgroups, timing strategies, and outcome domains may derive meaningful benefit. The following sections critically examine the evidence for individual SSRIs, beginning with FLX, the most extensively studied compound in this context. A structured summary of the available clinical evidence on individual SSRIs for post-stroke recovery is provided in Table 1.

One of the most critical interpretive challenges in the literature on SSRIs for post-stroke recovery lies in the apparent discrepancy between domain-specific improvements and the absence of benefit on global disability scales [24, 29–32, 42–44]. Across early mechanistic and smaller randomized studies, SSRIs were associated with measurable gains in motor subscores, executive function, dexterity, and neurophysiological indices of cortical reorganization. In contrast, large multicenter pragmatic trials consistently failed to demonstrate superiority over placebo on global functional endpoints, most assessed using the mRS. Recent meta-analyses have generally confirmed the absence of significant benefits of SSRIs on global functional outcomes. Overall, pooled evidence aligns more closely with the neutral findings of large multicenter RCTs than with the positive signals observed in smaller exploratory and mechanistic studies [45, 46]. This divergence raises important methodological and conceptual considerations. The mRS, while widely accepted as a robust and clinically meaningful endpoint in stroke trials, is inherently broad and ordinal, capturing overall disability rather than specific domains of recovery [47–49]. Its strength lies in measuring global independence [47]; however, it may lack sensitivity to detect subtle but biologically relevant improvements in motor control, cortical excitability, or higher-order cognitive functions [50, 51]. Thus, reliance on mRS as a sole primary endpoint may underestimate domain-specific and mechanistically relevant therapeutic effects.

In contrast, earlier mechanistic trials frequently employed more granular outcome measures, such as the FMMS, detailed neuropsychological batteries, transcranial magnetic stimulation parameters, and functional neuroimaging metrics. These tools are specifically designed to capture neuroplastic adaptations and localized functional changes, which may precede—or not necessarily translate into—detectable shifts in global disability categories.

Thus, the heterogeneity of findings may reflect, at least in part, a mismatch between the hypothesized mechanism of action of SSRIs and the outcome measures selected to evaluate their clinical impact. Importantly, stroke etiology may also influence treatment response. Most available evidence derives from ischemic stroke populations, while data on hemorrhagic stroke remain limited. Differences in underlying pathophysiology, including mechanisms of injury and patterns of recovery, may partly explain heterogeneity in SSRI effects across studies.

If SSRIs primarily modulate cortical excitability, enhance synaptic plasticity, and facilitate motor relearning in targeted domains, their effects may be diluted when assessed using broad composite scales that integrate mobility, self-care, cognition, and social participation into a single ordinal score. Furthermore, spontaneous recovery trajectories, rehabilitation intensity, and comorbidity burden may overshadow modest pharmacologically mediated gains when large heterogeneous populations are studied. Additional factors potentially contributing to this discrepancy include variability in rehabilitation intensity, differences in lesion location and size, heterogeneity in stroke subtype, and uncertainty regarding the optimal dose–duration relationship of serotonergic modulation. Within this context, the apparent contradiction between biological plausibility and clinical inefficacy may therefore be more methodological than pharmacological.

From a clinical standpoint, current evidence does not support the routine use of SSRIs as neurorestorative agents in non-depressed stroke patients. Similar to other classes of antidepressants [52–54], SSRIs have not consistently demonstrated a meaningful benefit on global functional outcomes. Large, high-quality RCTs have not demonstrated improvement in global functional outcomes and have consistently identified increased risks, including fractures, falls, seizures, and hyponatremia. These safety signals are particularly relevant in an already vulnerable population characterized by advanced age, polypharmacy, and frailty.

Nevertheless, it would be premature to conclude that serotonergic modulation lacks any rehabilitative relevance. A more nuanced interpretation suggests that potential benefits may be confined to specific subgroups and clinical contexts. Signals of potential efficacy have been suggested in settings such as early subacute ischemic stroke, particularly in patients with moderate motor deficits. Under these conditions—where a “window of enhanced plasticity” may exist—serotonergic augmentation could exert a permissive effect on experience-dependent reorganization. However, these observations should be considered hypothesis-generating rather than evidence-based conclusions.

The above-reported observations underscore the need to move beyond the binary question of whether SSRIs globally improve stroke outcomes and instead adopt a precision-medicine framework. Future research should prioritize the identification of biomarkers capable of stratifying responders from non-responders. Candidate markers include genetic polymorphisms affecting serotonergic transmission [55–57], BDNF levels [58–60], patterns of structural and functional connectivity on neuroimaging [9, 61], and electrophysiological measures of cortical excitability [62, 63]. Integrating such biomarkers into trial design could enable enriched trial designs, allowing for more precise patient selection and reducing the dilution of treatment effects in heterogeneous populations.

Equally critical is the optimization of treatment timing and duration. The neurobiological processes underlying post-stroke plasticity are temporally dynamic, suggesting that the therapeutic window for serotonergic modulation may be limited [64, 65]. Determining whether short-term early administration is superior to prolonged exposure, and whether therapeutic benefits plateau or adverse effects accumulate over time, remains an unresolved question.

Moreover, future trials should incorporate domain-specific primary endpoints aligned with mechanistic hypotheses, rather than relying exclusively on global disability scales. Hierarchical or composite outcome strategies, combining sensitive motor and cognitive measures with clinically meaningful functional endpoints, may provide a more comprehensive assessment of therapeutic impact. Stratification by stroke subtype, particularly ischemic versus hemorrhagic etiologies, also warrants systematic investigation, as underlying pathophysiology and plasticity patterns differ substantially.

In summary, current meta-analytic evidence and large multicenter RCTs do not support the routine use of SSRIs as neurorestorative agents in non-depressed stroke patients. However, the discrepancy between biological plausibility, domain-specific improvements, and neutral global functional outcomes highlights a critical need for methodological refinement rather than definitive abandonment of the concept. A shift toward biomarker-driven patient selection, mechanistically aligned endpoints, and temporally optimized intervention strategies may ultimately clarify whether serotonergic modulation holds a targeted, context-dependent role within precision neurorehabilitation paradigms. Collectively, these observations support a precision neurorehabilitation framework in which serotonergic modulation may be relevant only in biologically selected subgroups rather than as a universal therapeutic strategy.